← back to search

Rodolfo J. Galindo

University of Miami · US
Area of research
Endocrinology, Diabetes and Metabolism · Genetics
Research interest
Research interests include Diabetes Management and Research, Diabetes Treatment and Management, Hyperglycemia and glycemic control in critically ill and hospitalized patients, and Diabetes and associated disorders.
h-index
37
citations
6,572
works
213
NIH funding
primary concept
Medicine
email

Recent publications

Clinical Impact of Continuous Glucose Monitoring in Noninsulin Treated Type 2 Diabetes: A Review
Diabetes Technology & Therapeutics 2026cited by 2position: middledoi
GLP-1RA Use and Thyroid Cancer Risk
JAMA Otolaryngology–Head & Neck Surgery 2025cited by 44position: middledoi
Use of continuous glucose monitoring and point-of-care glucose testing in hospitalized patients with diabetes mellitus in non-intensive care unit settings: A systematic review and meta-analysis of randomized controlled trials
Diabetes Research and Clinical Practice 2025cited by 20position: middledoi
Moving Beyond Glycated Hemoglobin to Glucose Patterns: Newer Indications for Continuous Glucose Monitor Use
Endocrine Practice 2025cited by 11position: lastdoi
Prescribing Trends of Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes or Obesity
JAMA Network Open 2025cited by 10position: middledoi
Continuous ketone monitoring for people with diabetes: international expert recommendations on the application of a new technology
The Lancet Diabetes & Endocrinology 2025cited by 9position: middledoi
Continuous Glucose Monitoring Improves Detection of Glycemic Excursions in Hemodialysis Patients With Type 2 Diabetes
The Journal of Clinical Endocrinology & Metabolism 2025cited by 6position: firstdoi
Comparative effectiveness of GLP-1 receptor agonists on cardiovascular outcomes among adults with type 2 diabetes and moderate cardiovascular risk: emulation of a target trial
Diabetes Research and Clinical Practice 2025cited by 5position: middledoi
Improvement in body mass index category was associated with improved cardiometabolic measures and patient‐reported outcomes in adults with type 2 diabetes treated with tirzepatide
Diabetes Obesity and Metabolism 2025cited by 4position: firstdoi
Risk of Sight-Threatening Diabetic Retinopathy with Glucagon-Like Peptide-1 Receptor Agonist Use in Routine Clinical Practice
Ophthalmology Retina 2025cited by 4position: middledoi
Addressing the Diabetes Tsunami Requires Expanded Access to Diabetes Technologies
Journal of Diabetes Science and Technology 2025cited by 3position: middledoi
Wearable Diabetes Technology for Hospitalized People With Diabetes and End-Stage Kidney Disease, Peripartum State, and Steroid Use
Journal of Diabetes Science and Technology 2025cited by 3position: lastdoi
Hyperglycemic Crises in Adults With Diabetes: A Consensus Report
Diabetes Care 2024cited by 203position: middledoi
Hyperglycaemic crises in adults with diabetes: a consensus report
Diabetologia 2024cited by 116position: middledoi
Risks of peri‐ and <scp>postoperative</scp> complications with glucagon‐like peptide‐1 receptor agonists
Diabetes Obesity and Metabolism 2024cited by 46position: middledoi
The Diabetes Technology Society Error Grid and Trend Accuracy Matrix for Glucose Monitors
Journal of Diabetes Science and Technology 2024cited by 34position: middledoi
Continuous Glucose Monitoring for Prediabetes: What Are the Best Metrics?
Journal of Diabetes Science and Technology 2024cited by 33position: middledoi
Effectiveness of glucose-lowering medications on cardiovascular outcomes in patients with type 2 diabetes at moderate cardiovascular risk
Nature Cardiovascular Research 2024cited by 22position: middledoi
Consensus Report on the Use of Continuous Glucose Monitoring in Chronic Kidney Disease and Diabetes
Journal of Diabetes Science and Technology 2024cited by 20position: middledoi
Comparative Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, and Sulfonylureas for Sight-Threatening Diabetic Retinopathy
Ophthalmology Retina 2024cited by 18position: middledoi
Diabetes technology in people with diabetes and advanced chronic kidney disease
Diabetologia 2024cited by 16position: firstdoi
Derivation of an Annualized Claims-Based Major Adverse Cardiovascular Event Estimator in Type 2 Diabetes
JACC Advances 2024cited by 15position: middledoi
Diabetes Technology in People with Type 2 Diabetes: Novel Indications
Current Diabetes Reports 2024cited by 11position: middledoi
Should We Stop Glucagon-Like Peptide-1 Receptor Agonists Before Surgical or Endoscopic Procedures? Balancing Limited Evidence With Clinical Judgment
Journal of Diabetes Science and Technology 2024cited by 11position: lastdoi
Early-Onset Type 2 Diabetes and Tirzepatide Treatment: A Post Hoc Analysis From the SURPASS Clinical Trial Program
Diabetes Care 2024cited by 11position: middledoi
Randomized Study Comparing Continuous Glucose Monitoring and Capillary Glucose Testing in Patients With Type 2 Diabetes After Hospital Discharge
Endocrine Practice 2024cited by 9position: middledoi
Continuous Glucose Monitoring Metrics and Hemoglobin A1c Relationship in Patients with Type 2 Diabetes Treated by Hemodialysis
Diabetes Technology & Therapeutics 2024cited by 8position: firstdoi
Kidney Outcomes with Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, and Sulfonylureas in Type 2 Diabetes and Moderate Cardiovascular Risk
Clinical Journal of the American Society of Nephrology 2024cited by 6position: middledoi
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
The Lancet 2023cited by 653position: middledoi
American Association of Clinical Endocrinology Consensus Statement: Comprehensive Type 2 Diabetes Management Algorithm – 2023 Update
Endocrine Practice 2023cited by 349position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Guillermo E. Umpierrez · Emory University46 papers (2018–2025)Rozalina G. McCoy · University of Baltimore17 papers (2021–2025)Francisco J. Pasquel · Emory University16 papers (2018–2025)Priyathama Vellanki · Emory University14 papers (2018–2024)Georgia M. Davis · Emory University14 papers (2019–2024)Maya Fayfman · Emory University12 papers (2018–2023)Saumeth Cardona · Emory University11 papers (2018–2022)Kavya Swarna · Seattle University10 papers (2021–2025)Limin Peng · Emory University9 papers (2018–2024)Jeph Herrin · Yale Cancer Center9 papers (2022–2025)Alexandra L. Migdal · Emory University9 papers (2019–2022)Bonnie Albury · Emory University8 papers (2019–2022)Maria A. Urrutia · Emory University8 papers (2018–2021)Eric C. Polley · Chicago Department of Public Health7 papers (2024–2025)Grazia Aleppo · Northwestern University7 papers (2020–2026)Joshua J. Neumiller · Washington State University Spokane7 papers (2022–2025) · 6 papers (2024–2025) · 6 papers (2024–2025)Janet B. McGill · University of Colorado Denver5 papers (2021–2026)Elias K. Spanakis · University of Colorado Denver5 papers (2020–2023)